Videos
Neoadjuvant Pembrolizumab in Localized Mismatch Repair–Deficient Colon Cancer
05/15/2026
Clinical Summary:
- Design/Context: The phase 2 RESET-C trial evaluated a single cycle of neoadjuvant pembrolizumab in patients with stage I–III mismatch repair–deficient colon cancer.
- Key Outcomes: Pembrolizumab induced high rates of pathologic complete and major pathologic response with favorable early disease-free and overall survival outcomes.
- Clinical Relevance: These findings support immunotherapy-based response-adapted strategies in localized mismatch repair–deficient colon cancer and suggest potential future roles for organ preservation in selected patients.
Ismail Gögenur, MD, DMSc, Zealand University Hospital, Køge, Denmark, discusses results from the RESET-C trial evaluating a single cycle of neoadjuvant pembrolizumab in patients with mismatch repair–deficient (dMMR) colon cancer.
Results demonstrated that a single cycle produced substantial pathologic response with encouraging early oncologic outcomes, supporting future development of individualized and potentially organ-sparing treatment strategies.
Source:
Gögenur I, Justesen TF, Tarpgaard LS, et al. Neoadjuvant single-cycle pembrolizumab for stage I-III MMR-deficient colon cancer: The RESET-C trial. J Clin Oncol. Published online: May 5, 2026. doi:10.1200/JCO-25-02274
